PTC Therapeutics Discloses Lobbying Expenditures and Insider Trading

PTC Therapeutics has reported $20,000 in lobbying expenditures for the first quarter of 2025, as revealed in a recent filing under the Lobbying Disclosure Act.

Lobbying Focus

The company’s lobbying efforts included advocating for issues such as:

• Seeking drug approval through the FDA.

For further insights on corporate lobbying activities, visit Quiver Quantitative.

PTCT Insider Trading Activity

Over the last six months, insiders at PTC Therapeutics have executed 69 trades for $PTCT on the open market, with no purchases and all being sales. Here’s a summary of the recent trading activity:

• MARK ELLIOTT BOULDING (Exec. VP and CLO): 0 purchases, 19 sales, 193,337 shares sold, estimated value: $10,159,420.
• NEIL GREGORY ALMSTEAD (Chief Technical Ops Officer): 0 purchases, 14 sales, 77,535 shares sold, estimated value: $4,009,259.
• JEROME B ZELDIS: 0 purchases, 5 sales, 24,000 shares sold, estimated value: $1,235,897.
• CHRISTINE MARIE UTTER (SVP, Chief Accounting Officer): 0 purchases, 8 sales, 22,510 shares sold, estimated value: $1,142,121.
• MATTHEW B. KLEIN (Chief Executive Officer): 0 purchases, 5 sales, 20,615 shares sold, estimated value: $968,344.
• ERIC PAUWELS (Chief Business Officer): 0 purchases, 9 sales, 17,900 shares sold, estimated value: $945,231.
• STEPHANIE OKEY: 5,000 shares sold, estimated value: $270,000.
• LEE SCOTT GOLDEN (EVP & Chief Medical Officer): 0 purchases, 5 sales, 4,662 shares sold, estimated value: $220,196.
• PIERRE GRAVIER (Chief Financial Officer): 0 purchases, 2 sales, 2,335 shares sold, estimated value: $117,006.
• ALLAN STEVEN JACOBSON: 1,230 shares sold, estimated value: $63,369.

To monitor insider transactions, refer to Quiver Quantitative’s insider trading dashboard.

PTCT Hedge Fund Activity

In the latest quarter, 126 institutional investors increased their holdings in PTCT stock, while 91 reduced their positions. Highlights from recent institutional trading include:

• TORONTO DOMINION BANK: Added 3,286,729 shares (+inf%), valued at approximately $148,362,947.
• WELLINGTON MANAGEMENT GROUP LLP: Removed 3,105,676 shares (-39.3%), valued at approximately $140,190,214.
• DRIEHAUS CAPITAL MANAGEMENT LLC: Added 1,041,059 shares (+inf%), valued at approximately $46,993,403.
• UBS GROUP AG: Added 905,980 shares (+548.8%), valued at approximately $40,895,937.
• POINT72 ASSET MANAGEMENT, L.P.: Added 867,502 shares (+150.6%), valued at approximately $39,159,040.
• ARMISTICE CAPITAL, LLC: Removed 856,898 shares (-11.8%), valued at approximately $38,680,375.
• JACOBS LEVY EQUITY MANAGEMENT, INC: Removed 659,778 shares (-44.4%), valued at approximately $29,782,378.

For insights into hedge fund portfolios, visit Quiver Quantitative’s institutional holdings dashboard.

PTCT Analyst Ratings

In recent months, Wall Street analysts have provided ratings on $PTCT. Notably, two firms have issued buy ratings, while no firms have declared sell ratings. Here are some recent analyst evaluations:

• Cantor Fitzgerald issued an “Overweight” rating on 02/03/2025.
• RBC Capital issued an “Outperform” rating on 01/07/2025.

For more details on analyst ratings and price targets, see Quiver Quantitative’s $PTCT forecast page.

PTCT Price Predictions

Recent analyst assessments have resulted in price targets for $PTCT. In total, two analysts have provided price targets within the last six months, with a median target set at $55.0.

Recent targets include:

• Brian Abrahams from RBC Capital set a target price of $58.0 on 01/07/2025.
• Joel Beatty from Robert W. Baird set a target price of $52.0 on 11/27/2024.

This article is not financial advice. For more information, see Quiver Quantitative’s disclaimers.

This article was originally published on Quiver News; read the full story.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.